C7orf17; MNRR1; NS2TP; PARK22
The CHCHD2 gene currently has no well-established disease association; however, there is preliminary evidence supporting a correlation with autosomal dominant Parkinson’s disease 22 (PARK22) (PMID: 25662902, 26067110).
Order this gene as a single gene test.
Invitae tests that include this gene:
The CHCHD2 gene encodes a coiled-coil-helix-coiled-coil-helix protein that localizes to the intermembrane space of the mitochondria. It acts as a transcription factor binding and activating the oxygen responsive element of the COX4I2 gene, contributing to the regulation of COX4I2 expression in response to oxygen changes. CHCHD2 also inhibits mitochondria-mediated apoptosis.
Invitae is a College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified clinical diagnostic laboratory performing full-gene sequencing and deletion/duplication analysis using next-generation sequencing technology (NGS).
Our sequence analysis covers clinically important regions of each gene, including coding exons, +/- 10 base pairs of adjacent intronic sequence, and select noncoding variants. Our assay provides a Q30 quality-adjusted mean coverage depth of 350x (50x minimum, or supplemented with additional analysis). Variants classified as pathogenic or likely pathogenic are confirmed with orthogonal methods, except individual variants that have high quality scores and previously validated in at least ten unrelated samples.
Our analysis detects most intragenic deletions and duplications at single exon resolution. However, in rare situations, single-exon copy number events may not be analyzed due to inherent sequence properties or isolated reduction in data quality. If you are requesting the detection of a specific single-exon copy number variation, please contact Client Services before placing your order.
|Gene||Transcript reference||Sequencing analysis||Deletion/Duplication analysis|